 Wave Life Sciences Ltds NASDAQ: WVE closely-watched antisense oligonucleotide program crashed in an early-stage Huntingtons disease study, thus wiping out two experimental drug candidates. What Happened: WVE-120102 failed to separate from the placebo with no evidence of a dose-response on mutant Huntingtin protein mHTT at any of the doses. 